Evidence map›Paper›PMID 31973694›Full record

ArticleMalaria journal2020

Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis.

Lelisa Fekadu Assebe, Xiaoxiao Jiang Kwete, Dan Wang, Lingrui Liu, Ole Frithjof Norheim, Abdulrahman Jbaily, Stéphane Verguet, Kjell Arne Johansson, Mieraf Taddesse Tolla

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Lelisa Fekadu AssebeDepartment of Global Public Health and Primary Care Medicine, University of Bergen, Bergen, Norway.
Xiaoxiao Jiang KweteDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Dan WangSchool of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Lingrui LiuDepartment of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
Ole Frithjof NorheimDepartment of Global Public Health and Primary Care Medicine, University of Bergen, Bergen, Norway.
Abdulrahman JbailyDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Stéphane VerguetDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. verguet@hsph.harvard.edu.ORCID http://orcid.org/0000-0003-4128-0849
Kjell Arne JohanssonDepartment of Global Public Health and Primary Care Medicine, University of Bergen, Bergen, Norway.
Mieraf Taddesse TollaDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Harvard University · USUniversity of Bergen · NOXi'an Jiaotong University · CNYale University · US

Funding

Bill & Melinda Gates Foundation OPP1162384
6 · The paper itself

Abstract

backgroundMalaria is a public health burden and a major cause for morbidity and mortality in Ethiopia. Malaria also places a substantial financial burden on families and Ethiopia's national economy. Economic evaluations, with evidence on equity and financial risk protection (FRP), are therefore essential to support decision-making for policymakers to identify best buys amongst possible malaria interventions. The aim of this study is to estimate the expected health and FRP benefits of universal public financing of key malaria interventions in Ethiopia.

methodsUsing extended cost-effectiveness analysis (ECEA), the potential health and FRP benefits were estimated, and their distributions across socio-economic groups, of publicly financing a 10% coverage increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and malaria vaccine (hypothetical).

resultsACT, LLIN, IRS, and vaccine would avert 358, 188, 107 and 38 deaths, respectively, each year at a net government cost of $5.7, 16.5, 32.6, and 5.1 million, respectively. The annual cost of implementing IRS would be two times higher than that of the LLIN interventions, and would be the main driver of the total costs. The averted deaths would be mainly concentrated in the poorest two income quintiles. The four interventions would eliminate about $4,627,800 of private health expenditures, and the poorest income quintiles would see the greatest FRP benefits. ACT and LLINs would have the largest impact on malaria-related deaths averted and FRP benefits.

conclusionsACT, LLIN, IRS, and vaccine interventions would bring large health and financial benefits to the poorest households in Ethiopia.

Indexed as

Malaria VaccinesAnti-Infective AgentsArtemisininsCost-Benefit AnalysisEthiopiaHealth ExpendituresHumansIncidenceIncomeInsecticidesInsecticide-Treated BednetsMalariaRisk FactorsSocioeconomic FactorsAnti-Infective AgentsartemisininArtemisininsInsecticidesMalaria VaccinesEquityEthiopiaExtended cost-effectiveness analysisFinancial risk protectionMalaria

Identifiers

PMID31973694
PMCPMC6979328
OpenAlexW3013307117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.